Ruling disappoints Hoechst unit

Article Abstract:

Hoechst Marion Roussel, which is owned by Hoechst AG, was disappointed that its plan to market its propentofylline Alzheimer's medication in the European Union was rejected by the European Commission. The drug maker will be seeking written documents from the commission to explain its decision. The company indicated that the product, which can also be used for vascular dementia, can produce 750 million marks, or $457.5 million, in potential sales per year. A poor global market affected the firm's operating profit and earnings per share in 1998.

Comment:

Is disappointed that its plan to market its propentofylline Alzheimer's medication in EU was rejected by European Commission

European Union, Alzheimer Disease Controllers, Anti-Alzheimer's disease agents, Article, Hoechst Marion Roussel

---

Generic drug industry sues U.S. government

Article Abstract:

The generic drug industry has filed a lawsuit against the US government over new rules for pediatric drugs. The industry claims that the rules enable large pharmaceutical comapnies to gain unfair patent and market-exclusivity extensions for blockbuster pharmaceuticals. Two industry trade groups requested a federal court to prevent the US Food and Drug Administration from enforcing the new rules.

United States, Government regulation (cont), Patents & copyrights, Generic Drugs, Cases, Pharmaceutical industry, Abstract, United States. Food and Drug Administration

---

Gilead agrees to buy Myogen for $2.5 billion

Article Abstract:

Gilead Sciences Inc. is acquiring Myogen Inc., another biopharmaceuticals company. This will give Gilead Sciences ownership of Ambrisentan, a pulmonary arterial hypertension drug currently being tested.

Acquisitions & mergers, Drugs, Blood Pressure Preparations, Mergers, acquisitions and divestments, Company acquisition/merger, Testing, Drug therapy, Biological products industry, Gilead Sciences Inc., GILD, Pulmonary hypertension, Antihypertensive drugs, Antihypertensive agents, Myogen Inc., Ambrisentan (Medication)

Similar abstracts:

• Abstracts: The best energy drinks. Sweet summer delights. Sensational summer drinks
• Abstracts: Nonlinear price discrimination with a finite number of consumers and constrained recontracting. Regulation with non-price discrimination
• Abstracts: No way to treat an energy rating. Coffeehouse conversation
• Abstracts: Outsourcing must be more than cost cutting. Archstone wastes no time going multinational. Late to India, Hay Group gets traction
• Abstracts: Using neural networks to forecast the systematic risk of stocks. Sequential buying policies

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.